Characterization of pristane-induced arthritis, a murine model of chronic disease: Response to antirheumatic agents, expression of joint cytokines, and immunopathology

Arthritis and Rheumatism

Volumn 50, Issue 10, 2004, Pages 3334-3345

  Patten, Christopher ^a   Bush, Katherine ^a   Rioja, Inma ^a   Morgan, Rebecca ^b   Wooley, Paul ^b   Trill, John ^c   Life, Paul ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b HUTZEL HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIGEN; CELECOXIB; DICLOFENAC; ETANERCEPT; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MURINE SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PRISTANE; SB 242235; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; VISUAL ANALOG SCALE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; INTERLEUKIN-6; JOINTS; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PREDNISOLONE; TERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5644285350     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20507     Document Type: Article

References (32)

1. Potter M, Wax JS. Genetics of susceptibility of pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 1981;127:1591-5.
2. Wooley PH, Seibold JR, Whalen JD, Chapedelaine JM. Pristane-induced arthritis: the immunological and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum 1989;32:1022-30.
3. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83.
4. Stuart JM, Townes AS, Kang AH. Collagen autoimmune arthritis. Annu Rev Immunol 1984;2:199-218.
5. Kimpel D, Dayton T, Kannan K, Wolf RE. Streptococcal cell wall arthritis: kinetics of immune cell activation in inflammatory arthritis. Clin Immunol 2002;105:351-62.
6. Bedwell AE, Elson CJ, Hinton CE. Immunological involvement in the pathogenesis of pristane-induced arthritis. Scand J Immunol 1987;25:393-8.
7. Hopkins SJ, Freemont AJ, Jayson MIV. Pristane-induced arthritis in Balb/c mice. I. Clinical and histological features of the arthropathy. Rheumatol Int 1984;5:21-8.
8. Thompson SJ, Elson CJ. Susceptibility to pristane-induced arthritis is altered with changes in bowel flora. Immunol Lett 1993;36:227-31.
9. Thompson SJ, Francis, JN, Khai Siew L, Webb GR, Jenner PJ, Colston MJ, et al. An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. J Immunol 1998;160:4628-34.
10. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
11. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
12. Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann N Y Acad Sci 1993;696:149-70.
13. Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 2004;137:65-73.
14. Heid CA, Stevens, J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
15. Hopkins SJ, Freemont AJ, Jayson MI. Pristane-induced arthritis in BALB/c mice. Curr Top Microbiol Immunol 1985;122:213-20.
16. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
17. Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis [abstract]. Cochrane Database Syst Rev 2000;2:CD001158.
18. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
19. Kirwan JR, for the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
20. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold: extension of a one-year double blind study in 174 patients. Rheumatology (Oxford) 2002;41:196-204.
21. Van den Brink HR, van Wijk MJ, Geertzen RG, Bijlsma JW. Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis. J Rheumatol 1994;21:430-4.
22. Nishikaku F, Aono S, Koga Y. Protective effects of D-penicillamine and a thiazole derivative, SM-8849, on pristane-induced arthritis in mice. Int J Immunopharmacol 1993;16:91-100.
23. Hinson R, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996;93:4885-90.
24. Shacter E, Arzadon GK, Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 1992;80:194-202.
25. Bloquel C, Bessis N, Boissier M-C, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-α soluble receptor I variants. Hum Gene Ther 2004;15:189-201.
26. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999;163:1000-9.
27. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
28. LaPointe MC, Isenovic E. Interleukin-1β regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999;33:276-82.
29. Svensson CI, Hua XY, Frotter AA, Powell HC, Yaksh TL. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 2003;14:1153-7.
30. Piao CS, Kim JB, Han PL, Lee JK. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res 2003;73:537-44.
31. De Laszlo SE, Visco D, Agarwal L, Chang L, Chin J, Croft G, et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998;8:2689-94.
32. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81.